AOD-9604 Dosage: What Human Trials Really Showed

AOD-9604 dosage looks deceptively simple until you check what actually happened in human trials. The answer is direct: the public record never produced a single winning protocol, and the clearest evidence comes from once-daily oral studies—not from the injectable routines you see discussed online.

Start with the route, not the micrograms

AOD-9604 is a growth-hormone fragment built from the 176-191 region, but dosage clarity breaks down when people mix oral obesity-trial data with later compounding-era injection practices. If you've already read our AOD-9604 overview, this is the narrower follow-up: what was actually tested in humans, and what came afterward. One more context piece: the FDA currently lists AOD-9604 among compounded substances that may present significant safety risks current FDA posture.

• 12-week oral trial program: 1, 5, 10, 20, or 30 mg once daily.
• Later oral OPTIONS study: 0.25, 0.5, or 1 mg once daily.
• Current injection routines: widely discussed, but they don't have the same clinical backing as the earlier oral trials.

What the human trials actually used

The strongest early signal came from a 12-week oral phase IIa study later documented in the AOD9604 safety paper: 300 adults with obesity were randomized (after a placebo run-in) to once-daily placebo or doses of 1, 5, 10, 20, or 30 mg of AOD9604. Here's the striking finding: the 1 mg arm, not the bigger doses, produced the clearest weight-loss signal. This is why AOD-9604 dosage conversations still center on that surprisingly low once-daily starting point in the literature trial safety summary.

Then came the study that reset the entire dosage conversation. Metabolic's 536-subject OPTIONS trial kept the oral route but dropped the doses further: 0.25, 0.5, and 1 mg once daily, measured over 24 weeks with the primary endpoint at 12 weeks. The result: no significant advantage over placebo. This is why AOD-9604 dosage remains unsettled—the larger trial didn't confirm the promise of the smaller one OPTIONS study design.

Why injection chatter got louder anyway

AOD-9604 stayed alive in compounding and wellness clinics long after the formal obesity-drug development stopped. That's where the 300–500 mcg injection routines come from—and why you see them framed online as if they were the main clinical evidence. They're not. They live in a completely different category from the earlier oral trials, and deserve more caution than an established injectable option like semaglutide injection.

How to read AOD-9604 dosage claims without getting lost

• Check the route first. Oral trial data and injectable community use are two different things.
• Treat the 1 mg oral finding as an opening signal, not a settled standard.
• Weight the larger trial heavily. Dosage claims that skip over it are selling you only half the story.

That last point is the real dividing line between older peptide research and current obesity-treatment evidence. If you want a routine backed by larger modern efficacy data, tirzepatide weight loss offers a much clearer benchmark than any AOD-9604 dosing formula.

Bottom line

AOD-9604 dosage comes into focus when you ask the right question: which evidence era are you actually looking at? The public obesity trials point first to once-daily oral regimens, especially the 1 mg result in the smaller early study, then directly to a larger trial that disrupted the entire narrative. The result: AOD-9604 isn't a protocol winner—it's a research peptide with one strong early signal and a much more complicated follow-up.